Anjana Bhardwaj, MS, PhD
Department of Breast Surgical Oncology, Division of Surgery
Present Title & Affiliation
Primary Appointment
Associate Professor, Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Dr. Anjana Bhardwaj is a cancer scientist with strong background in cancer prevention research. She has authored numerous publications studying various aspects of cancer biology, chemoprevention, RNA, miRNA and gene regulation. Characterization of molecular changes that occur early in the development of breast cancer and their targeting for breast prevention has been the focus of her long-standing research efforts. In recent years, Dr Bhardwaj has focused her research efforts to identify neoantigens that are generated during cancer development and can be developed into cancer prevention vaccines. Currently she is working towards developing an off-the shelf neoantigen based multi-valent vaccine to prevent breast cancer in women with germline BRCA 1 and BRCA 2 mutations.
Clinical Interests
N/A
Education & Training
Degree-Granting Education
| 2002 | Post Graduate Institute of Medical Education and Research, Chandigarh, IN, Cancer Biology, Ph.D |
| 1997 | Panjab University, Chandigarh, IN, Biophysics, M.S |
| 1994 | Panjab University, Chandigarh, IN, Biophysics, B.S |
Postgraduate Training
| 2003-2008 | Post Doc Fellow, Molecular Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2002-2003 | Post Doc Fellow, Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2022
Instructor, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2013
Instructor, Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, 2009 - 2011
Instructor, Biochemistry and Molecular Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2008 - 2009
Demonstrator, Biophysics, Post Graduate Institute of Medical Education and Research, Chandigarh, 2000 - 2002
Administrative Appointments/Responsibilities
IACUC- Vice Chair, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2025 - Present
Research Faculty Lead, Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Extramural Institutional Committee Activities
Member, DoS Research Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Research Integrity Inquiry Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, IACUC, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Editorial Activities
Associate Editor, BMC Cancer, 2021 - Present
Honors & Awards
| 2006 | Best Oral Presentation Award, Texas Forum For Reproductive Sciences |
| 2005 | Lalor Foundation Fellowship, Lalor Foundation |
| 2002 | K. S. Koregaonkar Award, Indian Society of Biophysics |
| 2002 | Institute Fellowship, Post Graduate Institute of Medical Education and Research |
| 1998 - 2000 | PGIMER fellow, Post Graduate Institute of Medical Education and Research |
| 1998 | GATE Fellow, Graduate Aptitude Test in Engineering (GATE) |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2022. Biomarkers of statin response for prevention of breast cancer and predicting resistance to statins. Conference. Biomarkers of statin response for prevention of breast cancer and predicting resistance to statins. Houston, TX, US.
- 2022. Utility of gross tumor palpability or tumor size as a measure of drug efficacy for cancer prevention. Conference. Utility of gross tumor palpability or tumor size as a measure of drug efficacy for cancer prevention. Houston, TX, US.
- 2022. Long-term avasimibe treatment abolishes the breast cancer preventative efficacy of statin in a spontaneous mouse model of breast cancer. Conference. Long-term avasimibe treatment abolishes the breast cancer preventative efficacy of statin in a spontaneous mouse model of breast cancer. Houston, TX, US.
Regional Presentations
- 2025. RNA Fusions: An Untapped Source of Neoantigens for Immune-Based Breast Cancer Prevention. Invited. Advancing Cancer Treatment and Prevention: Vaccines Targeting Immunogenic Neoantigens Expressed from RNA Fusions and Immune Checkpoint Blockade for Neoadjuvant Therapies. Zoom meeting, US.
- 2011. Identification and localization of UTP14A in mouse testis. Conference. Identification and localization of UTP14A in mouse testis. Houston, TX, US.
- 2006. AR and GATA factors collaborate to drive Sertoli cell specific expression of the Pem (Rhox-5) proximal promoter in the testis. Conference. AR and GATA factors collaborate to drive Sertoli cell specific expression of the Pem (Rhox-5) proximal promoter in the testis. Houston, TX, US.
National Presentations
- 2025. Chimeric RNA driven neopeptide vaccine for prevention of breast cancer in germline BRCA1/2 carriers. Invited. Cancer Immunoprevention Network (CIP-Net) Steering Committee Meeting. Zoom meeting, US.
- 2025. Chimeric RNA driven neopeptide vaccine for prevention of breast cancer in germline BRCA1/2 carriers. Invited. Cancer Immunoprevention Network (CIP-Net) Kick-off Meeting. Washington, D.C, District of Columbia, US.
- 2024. Chimeric RNAs are abundantly expressed in precancerous breast tissue of sporadic breast cancer patients. Poster. AACR Annual Meeting. San Diego, California, US.
- 2023. Subtype-specific molecular signatures of field cancerization in patients with sporadic breast cancer. Conference. Subtype-specific molecular signatures of field cancerization in patients with sporadic breast cancer. Orlando, FL, US.
- 2023. Avasimibe abolishes the breast cancer preventative efficacy of statin in a spontaneous mouse model of breast cancer. Conference. Avasimibe abolishes the breast cancer preventative efficacy of statin in a spontaneous mouse model of breast cancer. Orlando, FL, US.
- 2021. Heterogeneity of preneoplastic breast tissues drives efficacy of therapeutic agents. Conference. Heterogeneity of preneoplastic breast tissues drives efficacy of therapeutic agents. San Antonio, TX, US.
- 2021. Stage of Preneoplastic Breast Cancer Progression Impacts the Efficacy of Chemoprevention. Conference. Stage of Preneoplastic Breast Cancer Progression Impacts the Efficacy of Chemoprevention, US.
- 2021. Gene signature of fluvastatin resistance for prevention of breast cancer and predicting resistance to statins. Conference. Gene signature of fluvastatin resistance for prevention of breast cancer and predicting resistance to statins. Virtual, DC, US.
- 2020. Fluvastatin inhibits the development of breast cancer in SV40C3Tag mouse model of triple negative breast cancer. Conference. Fluvastatin inhibits the development of breast cancer in SV40C3Tag mouse model of triple negative breast cancer. Virtual, US.
- 2019. Fluvastatin inhibits the development of breast cancer in SV40C3Tag mouse model of triple negative breast cancer. Conference. Fluvastatin inhibits the development of breast cancer in SV40C3Tag mouse model of triple negative breast cancer. Houston, TX, US.
- 2019. A GLOBAL INCREASE IN miRNAs AND A CONCOMITANT DECREASE IN TUMOR SUPPRESSOR PATHWAYS DEFINE PRENEOPLASTIC TRANSITION IN TNBC. Conference. A GLOBAL INCREASE IN miRNAs AND A CONCOMITANT DECREASE IN TUMOR SUPPRESSOR PATHWAYS DEFINE PRENEOPLASTIC TRANSITION IN TNBC. Houston, US.
- 2019. A GLOBAL INCREASE IN miRNAs AND A CONCOMITANT DECREASE IN TUMOR SUPPRESSOR PATHWAYS DEFINE PRENEOPLASTIC TRANSITION IN TNBC. Conference. A GLOBAL INCREASE IN miRNAs AND A CONCOMITANT DECREASE IN TUMOR SUPPRESSOR PATHWAYS DEFINE PRENEOPLASTIC TRANSITION IN TNBC. Atlanta, GA, US.
- 2018. IsomiR-140-3p regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer. Conference. IsomiR-140-3p regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer. San Antonio, TX, US.
- 2017. Stage of Preneoplastic Breast Cancer Progression Impacts the Efficacy of Chemoprevention. Conference. Stage of Preneoplastic Breast Cancer Progression Impacts the Efficacy of Chemoprevention. Houston, US.
- 2017. Stage of Preneoplastic Breast Cancer Progression Impacts the Efficacy of Chemoprevention. Conference. Stage of Preneoplastic Breast Cancer Progression Impacts the Efficacy of Chemoprevention. Los Angeles, CA, US.
- 2017. Repurposing statins for prevention of TNBC. Conference. Repurposing statins for prevention of TNBC. Houston, US.
- 2016. Regulation of miRNA-29c and its gene targets in preneoplastic progression of TNBC. Conference. Regulation of miRNA-29c and its gene targets in preneoplastic progression of TNBC. San Antonio, TX, US.
- 2015. Targeting miRNA networks for prevention of triple negative breast cancer. Conference. Targeting miRNA networks for prevention of triple negative breast cancer. Houston, TX, US.
- 2013. Suppression of Akt-mTOR pathway: a novel component of oncogene induced DNA damage response (DDR) barrier in breast. Conference. Suppression of Akt-mTOR pathway: a novel component of oncogene induced DNA damage response (DDR) barrier in breast. Washington, DC, US.
- 2013. miR-34a as a radio sensitizer of triple negative breast cancer. Conference. miR-34a as a radio sensitizer of triple negative breast cancer. Washington, DC, US.
- 2008. Spatial and temporal expression of Rhox5 homeobox gene in the epididymis is controlled by DNA methylation, androgen receptor, and GATA transcription factors. Conference. Spatial and temporal expression of Rhox5 homeobox gene in the epididymis is controlled by DNA methylation, androgen receptor, and GATA transcription factors. Kona, HI, US.
International Presentations
- 2016. Targeting of miRNA networks by natural/ synthetic compounds for prevention of basal like breast cancers. Conference. DDNPTM-2016. Mohali, IN.
Formal Peers
- 2024. Molecular characterization of breast cancer progression for prevention. Houston, Texas, US.
- 2023. Identification and targeting of early molecular changes for breast cancer prevention. Invited, US.
- 2023. Identification and targeting of early molecular changes for breast cancer prevention. Invited, US.
- 2019. Targeting iso-miRNA-140-3p mediated upregulation in cholesterol pathway for prevention of breast cancer. Invited, IN.
- 2017. Targeting miRNA networks for prevention of triple negative breast cancer. Invited, US.
- 2016. Targeting of miRNA networks for prevention of triple negative breast cancer. Invited, IN.
Grant & Contract Support
| Date: | 2025 - Present |
| Title: | Chimeric RNA driven neopeptide vaccine for prevention of breast cancer in germline BRCA 1/2 carriers |
| Funding Source: | NCI |
| Role: | PI |
| ID: | 1UG3CA290454-01A1 |
| Date: | 2024 - 2027 |
| Title: | “Chimeric RNA derived neoantigens as peptide vaccines for primary prevention of breast cancer” |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Co-I |
| Date: | 2024 - 2025 |
| Title: | Identification of recurrent somatic RNA fusions and neopeptides from preneoplastic breast tissue of germline BRCA1 /2 mutant carrier patients |
| Funding Source: | Institutional Research Grant |
| Role: | PI |
| Date: | 2024 - 2025 |
| Title: | “Chimeric RNA derived neoantigens as peptide vaccine for primary prevention of breast cancer” |
| Funding Source: | Institutional, Bridge Funding |
| Role: | Co-PI |
| Date: | 2024 - 2029 |
| Title: | “Chimeric RNA driven neopeptide vaccine for prevention of breast cancer in germline BRCA 1/2 carriers” |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Date: | 2024 - 2027 |
| Title: | “Chimeric RNA derived neoantigens as peptide vaccine for primary prevention of breast cancer” |
| Funding Source: | Breast Cancer Research Foundation |
| Role: | Co-I |
| Date: | 2024 - Present |
| Title: | Neopeptide vaccine for prevention of breast cancer in germline BRCA 1/2 carriers |
| Funding Source: | Cancer Prevention Initiative |
| Role: | Co-PI |
| Date: | 2023 - 2024 |
| Title: | Study TitleChimeric RNA-Derived Neoantigens as peptide vaccine for primary prevention of breast cancer |
| Funding Source: | Institutional Funding |
| Role: | Co-PI |
| Date: | 2021 - 2022 |
| Title: | Characterization of immune escape during breast cancer progression and its targeting for breast cancer prevention |
| Funding Source: | MDACC, Institutional funding |
| Role: | Co-PI |
| ID: | Institutional Grant-Adverse Incident Bridge Funding |
| Date: | 2020 - Present |
| Title: | Breast Cancer Prevention Research |
| Funding Source: | Nancy Owen Breast Cancer Foundation grant |
| Role: | Co-I |
| Date: | 2020 - Present |
| Title: | Targeting immune microenvironment for prevention of breast cancer |
| Funding Source: | Johnson & Johnson WiSTEM Scholars Award |
| Role: | PI |
| Date: | 2020 - Present |
| Title: | Deciphering the radiogenomic and immunologic alterations that drive progression to invasive breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2019 - Present |
| Title: | Targeting the cholesterol pathway for prevention of breast cancer |
| Funding Source: | Institutional -DRP |
| Role: | Co-I |
| Date: | 2019 - Present |
| Title: | Targeting macrophage polarization switch for prevention of breast cancer |
| Funding Source: | Prevent Cancer Foundation |
| Role: | PI |
| Date: | 2019 - Present |
| Title: | Alterations in macrophage- and T helper cell- polarization act to enable the step wise progression to invasive breast cancer |
| Funding Source: | IRG |
| Role: | Co-I |
| Date: | 2019 - Present |
| Title: | Cholesterol pathway targeting by fluvastatin for prevention of breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Date: | 2019 - 2024 |
| Title: | OPTIMIST Trial: Optimizing statin intervention for primary prevention of breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2019 - 2023 |
| Title: | OPTIMIST Trial: Optimizing statin intervention for primary prevention of breast cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Date: | 2018 - Present |
| Title: | Phase IIb trial of statin +/- ASA chemoprevention for women at high risk for breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2018 - 2023 |
| Title: | miRNA-140-3p-1 mediated deregulation of cholesterol pathway as a target for prevention of breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 |
| Date: | 2018 - 2022 |
| Title: | OPTIMIST Trial: Optimizing statin intervention for primary prevention of breast cancer |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Co-I |
| ID: | DOD LOI, level III |
| Date: | 2017 - Present |
| Title: | Characterization of preneoplastic miRNA signature for sporadic TNBC risk across racial populations |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | Breakthrough Award |
| Date: | 2017 - Present |
| Title: | Novel strategies for prevention of triple negative breast cancer |
| Funding Source: | Earlier.org |
| Role: | Co-I |
| Date: | 2017 - Present |
| Title: | Developing a framework for identification of functional miRNA-mRNA gene pairs for prevention of triple negative breast cancer |
| Funding Source: | IRG |
| Role: | Co-I |
| ID: | IRG |
| Date: | 2017 - Present |
| Title: | Novel strategies for prevention of triple negative breast cancer |
| Funding Source: | Prevent Cancer Foundation |
| Role: | Co-I |
| ID: | Foundation grant |
| Date: | 2017 - 2019 |
| Title: | Preneoplastic miRNA signature for sporadic TNBC risk across racial populations |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | R21 CA219219-01 |
| Date: | 2017 - 2018 |
| Title: | Repurposing statins for prevention of triple negative breast cancer |
| Funding Source: | Institutional (Breast Cancer moonshot) |
| Role: | Co-I |
| Date: | 2016 - 2017 |
| Title: | miRNA-mRNA functional gene pair for prevention of triple negative breast cancer |
| Funding Source: | Institutional Funding |
| Role: | Co-PI |
| Date: | 2016 - 2018 |
| Title: | “Targeting of miRNA-140 and its downstream pathway for prevention of triple negative breast cancer” |
| Funding Source: | DFI |
| Role: | Co-I |
| ID: | Duncan Family Institute |
| Date: | 2016 - Present |
| Title: | miRNA-29c regulation of tumorigenesis in triple negative breast cancer; opportunity for prevention and epigenomics based risk prediction |
| Funding Source: | Duncan Family Foundation |
| Role: | Co-I |
| Date: | 2016 - Present |
| Title: | Targeting of mIRNA-140 and its functional gene pairs for prevention of triple negative breast cancer |
| Funding Source: | DFI |
| Role: | Co-I |
| Date: | 2016 - Present |
| Title: | miRNA-mRNA functional gene pairs for prevention of triple negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R21 |
| Date: | 2016 - 2019 |
| Title: | Targeting miRNA-functional gene targets for prevention of sporadic triple negative breast cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | IIRA |
| Date: | 2015 - 2022 |
| Title: | Integrative molecular and imaging approaches for risk of subtype specific breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1U01CA189240-01 |
| Date: | 2015 - 2016 |
| Title: | Identifying Targets for Prevention of Sporadic, Triple Negative Breast Cancer |
| Funding Source: | Institutional Funding |
| Role: | Co-PI |
| Date: | 2015 - Present |
| Title: | Validation of a TNBC specific preneoplastic signature across different ethnic populations |
| Funding Source: | SINF |
| Role: | Co-I |
| Date: | 2015 - Present |
| Title: | Identifying targets for prevention of sporadic triple negative breast |
| Funding Source: | McCombs |
| Role: | Co-I |
| Date: | 2015 - 2018 |
| Title: | Targeting genomic and epigenomic signatures regulated by microRNA-29c-DNMT3A for prevention of basal like breast cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | CPRIT |
| Date: | 2011 - 2013 |
| Title: | Does IGF-1 signaling sensitize mammary epithelial cells to oncogene induced DNA damage and increase breast cancer risk |
| Funding Source: | Society of Surgical Oncology |
| Role: | Co-I |
Selected Publications
Peer-Reviewed Articles
- Bhardwaj, A, Koh, A, Embury, MD, Sandhu, J, Rojo, RD, Albarracin, C, Bedrosian, I. Gross tumor assessment is not a reliable measure of the efficacy of chemo-preventive agents for breast cancer in preclinical mouse models. Scientific reports 15(1), 2025. e-Pub 2025. PMID: 41219225.
- Bhardwaj, A, Koh, A, Bhala, R, Sandhu, J, Ju, Z, Cando, LF, Wang, J, Bedrosian, I. Avasimibe Abolishes the Efficacy of Fluvastatin for the Prevention of Cancer in a Spontaneous Mouse Model of Breast Cancer. International journal of molecular sciences 26(6), 2025. e-Pub 2025. PMID: 40141147.
- Mistretta, B, Rankothgedera, S, Castillo, M, Rao, M, Holloway, K, Bhardwaj, A, El Noafal, M, Albarracin, C, El-Zein, R, Rezaei, H, Su, X, Akbani, R, Shao, XM, Czerniecki, BJ, Karchin, R, Bedrosian, I, Gunaratne, PH. Chimeric RNAs reveal putative neoantigen peptides for developing tumor vaccines for breast cancer. Frontiers in immunology 14, 2023. e-Pub 2023. PMID: 37744342.
- Bhardwaj A, Rojo RD, Ju Z, Koh A, Tachibana K, Wang J, Bedrosian I. The molecular heterogeneity of the precancerous breast affects drug efficacy. Sci Rep 12(1):12590, 2022. e-Pub 2022. PMID: 35869155.
- Bhardwaj A, Embury MD, Ju Z, Wang J, Bedrosian I. Gene signature associated with resistance to fluvastatin chemoprevention for breast cancer. BMC Cancer 22(282):282, 2022. e-Pub 2022. PMID: 35296281.
- Bhardwaj A, Sohni A, Lou CH, De Gendt K, Zhang F, Kim E, Subbarayalu P, Chan W, Kerkhofs S, Claessens F, Kimmins S, Rao MK, Meistrich M, Wilkinson MF. Concordant Androgen-Regulated Expression of Divergent Rhox5 Promoters in Sertoli Cells. Endocrinology 163(1):bqab237, 2022. e-Pub 2022. PMID: 34902009.
- Bhardwaj A, Embury MD, Rojo RD, Albarracin C, Bedrosian I. Efficacy of fluvastatin and aspirin for prevention of hormonally insensitive breast cancer. Breast Cancer Res Treat 187(2):364-374, 2021. e-Pub 2021. PMID: 33893908.
- Ju1 Z, *, Bhardwaj2 A, *, Embury2 MD, Singh2 H, Gunaratne3 P, Bedrosian2 I, †, Wang1 J, †. Integrative analyses of multi-level omics reveal preneoplastic breast to possess a molecular landscape that is globally shared with invasive basal-like breast cancer. Cancers 12(3), 2020. e-Pub 2020. PMID: 32204397.
- Bhardwaj A, Singh H, Trinidad CM, Albarracin CT, Hunt KK, Bedrosian I. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer. Breast Cancer Res 20(1):150, 2018. e-Pub 2018. PMID: 30537987.
- Bhardwaj A, Singh H, Rajapakshe K, Tachibana K, Ganesan N, Pan Y, Gunaratne PH, Coarfa C, Bedrosian I. Regulation of miRNA-29c and its downstream pathways in preneoplastic progression of triple-negative breast cancer. Oncotarget 8(12):19645-19660, 2017. e-Pub 2017. PMID: 28160548.
- Bhardwaj, A, Ganesan, N, Tachibana, K, Rajapakshe, K, Albarracin, C, Gunaratne, PH, Coarfa, C, Bedrosian, I. Annexin A1 preferentially predicts poor prognosis of basal-like breast cancer patients by activating mTOR-S6 signaling. PloS one 10(5), 2015. e-Pub 2015. PMID: 26000884.
- Bhardwaj A, Ganesan N, Tachibana K, Rajapakshe K, Albarracin CT, Gunaratne PH, Coarfa C, Bedrosian AI. Annexin A1 overexpression preferentially predicts poor prognosis of basal-like breast cancer patients by activating mTOR-S6 signaling. PLoS One 10(5):e1027678, 2015. e-Pub 2015.
- Rao MK, Matsumoto Y, Richardson ME, Panneerdoss S, Bhardwaj A, Ward JM, Shanker S, Bettegowda A, Wilkinson MF. Hormone- and DNA Demethylation-Induced Relief of a Tissue-Specific and Developmentally Regulated Block in Transcriptional Elongation. J Biol Chem 289(51):35087-101, 2014. e-Pub 2014. PMID: 25331959.
- Bhardwaj A, Rosen D, Liu M, Liu Y, Hao Q, Ganesan N, Etzel CJ, Gullett A, Albarracin CT, Bedrosian I. Suppression of Akt-mTOR pathway-a novel component of oncogene induced DNA damage response barrier in breast tumorigenesis. PLoS One 9(5):e97076, 2014. e-Pub 2014. PMID: 24811059.
- Bhardwaj A, Song HW, Beildeck M, Kerkhofs S, Castoro R, Shanker S, De Gendt K, Suzuki K, Claessens F, Issa JP, Orgebin-Crist MC, Wilkinson MF. DNA demethylation-dependent AR recruitment and GATA factors drive Rhox5 homeobox gene transcription in the epididymis. Mol Endocrinol 26(4):538-49, 2012. e-Pub 2012. PMID: 22322598.
- Bruno IG, Karam R, Huang L, Bhardwaj A, Lou CH, Shum EY, Song HW, Corbett MA, Gifford WD, Gecz J, Pfaff SL, Wilkinson MF. Identification of a MicroRNA that Activates Gene Expression by Repressing Nonsense-Mediated RNA Decay. Mol Cell 42(4):500-10, 2011. e-Pub 2011. PMID: 21596314.
- Maclean JA, Bettegowda A, Kim BJ, Lou CH, Yang SM, Bhardwaj A, Shanker S, Hu Z, Fan Y, Eckardt S, McLaughlin KJ, Skoultchi AI, Wilkinson MF. The rhox homeobox gene cluster is imprinted and selectively targeted for regulation by histone h1 and DNA methylation. Mol Cell Biol 31(6):1275-87, 2011. e-Pub 2011. PMID: 21245380.
- Bhardwaj A, Rao MK, Kaur R, Buttigieg MR, Wilkinson MF. GATA factors and androgen receptor collaborate to transcriptionally activate the Rhox5 homeobox gene in Sertoli cells. Mol Cell Biol 28(7):2138-53, 2008. e-Pub 2008. PMID: 18212046.
- Hu Z, MacLean JA, Bhardwaj A, Wilkinson MF. Regulation and function of the Rhox5 homeobox gene. Ann N Y Acad Sci 1120:72-83, 2007. e-Pub 2007. PMID: 18184911.
- Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S, Aggarwal BB. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 109(6):2293-302, 2007. e-Pub 2007. PMID: 17164350.
- Li S, Wilkinson M, Xia X, David M, Xu L, Purkel-Sutton A, Bhardwaj A. Induction of IFN-regulated factors and antitumoral surveillance by transfected placebo plasmid DNA. Mol Ther 11(1):112-9, 2005. e-Pub 2005. PMID: 15585412.
- Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 23(57):9247-58, 2004. e-Pub 2004. PMID: 15489888.
- Khanduja KL, Bhardwaj A, Kaushik G. Resveratrol inhibits N-nitrosodiethylamine- induced ornithine decarboxylase and cyclooxygenase in mice. J Nutr Sci Vitaminol (Tokyo) 50(1):61-5, 2004. e-Pub 2004. PMID: 15228220.
- Khanduja, KL, Bhardwaj, A. Stable free radical scavenging and antiperoxidative properties of resveratrol compared in vitro with some other bioflavonoids. Indian Journal of Biochemistry and Biophysics 40(6):416-422, 2003. e-Pub 2003. PMID: 22900369.
- Khanduja KL, Bhardwaj A. Stable free radical scavenging and antiperoxidative properties of resveratrol compared in vitro with some other bioflavonoids. Ind. J. Biotechnology, 2003. e-Pub 2003.
- Khanduja, KL, Sangari, RK, Bhardwaj, A. Caffeine, quercetin and alizarin stimulate the exhalation of metabolic products of [14C]-N-nitrosodiethylamine in mice. Indian Journal of Experimental Biology 40(6):739-744, 2002. e-Pub 2002. PMID: 12587722.
- Sharma, RN, Bhardwaj, A, Behera, D, Khanduja, KL. Oxidative burden and antioxidant defense system in polymorphonuclear leukocytes of human lung diseases. Indian Journal of Biochemistry and Biophysics 39(2):124-129, 2002. e-Pub 2002. PMID: 22896900.
- Sharma, RN, Bhardwaj A, Khanduja, KL. Oxidative burden and antioxidant defense system in polymorphonuclear leukocytes of human lung diseases. Indian Journal of Biochemistry and Biophysics, 2002. e-Pub 2002.
- Bhardwaj, A, Gandhi, RK, Khanduja, KL. Alizarin inhibits oxidative damage and lung tumors in mice induced by N-nitrosodiethylamine. International Journal of Medicine, Biology and the Environment 29(1):85-90, 2001. e-Pub 2001.
- Khanduja, KL, Verma, A, Bhardwaj, A. Impairment of human sperm motility and viability by quercetin is independent of lipid peroxidation. Andrologia 33(5):277-281, 2001. e-Pub 2001. PMID: 11683702.
- Khanduja, K L, Verma, A, Bhardwaj A. Impairment of human sperm motility by quercetin is independent of lipid peroxidation. Andrologia 33(5):277-281, 2001. e-Pub 2001.
- Khanduja, KL, Sangari, RK, Bhardwaj, A. Caffeine, Quercetin and Alizarin stimulate the exhalation of metabolic end products of [14C]-N-nitrosodiethylamine in mice. Indian Journal of Experimental Biology, 2001. e-Pub 2001.
- Bhardwaj A, Khanduja, KL, (2001) SR. Alizarin inhibits oxidative damage and lung tumors in mice induced by N-nitrosodiethylamine. International Journal of Medicine Biology and Environment, 2001. e-Pub 2001.
- Bhardwaj, A, Verma, A, Majumdar, S, Khanduja, KL. Status of vitamin E and reduced glutathione in semen of oligozoospermic and azoospermic patients. Asian journal of andrology 2(3):225-228, 2000. e-Pub 2000. PMID: 11225982.
- Bhardwaj A, Verma, A, Majumdar, S, Khanduja, K L. Status of vitamin E and reduced glutathione in semen of oligozoospermic and azoospermic patients. Asian Journal of Andrology 2(3):161-166, 2000. e-Pub 2000.
Review Articles
- Bhala, R, Cando, LF, Verma, P, Adesoye, T, Bhardwaj, A. Biomarkers Predicting Progression and Prognosis of Ductal Carcinoma In Situ (DCIS). Anticancer research 45(4):1305-1328, 2025. e-Pub 2025. PMID: 40155037.
- Bhardwaj A, Wilkinson MF. A metabolic enzyme doing double duty as a transcription factor. BioEssays 27(5):467-71, 2005. e-Pub 2005. PMID: 15832388.
- Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24(5A):2783-840, 2004. e-Pub 2004. PMID: 15517885.
- Bhardwaj A, Aggarwal BB. Receptor-mediated choreography of life and death. J Clin Immunol 23(5):317-32, 2003. e-Pub 2003. PMID: 14601641.
Other Articles
- Bhardwaj, A, Sethi, G, Vadhan, S Erratum. Blood 122(7):1325-1326, 2013.
Abstracts
- Bhardwaj A, Koh A, Ju Z, Bhala R, Wang J, Bedrosian I. Avasimibe abolishes the breast cancer preventative efficacy of statin in a spontaneous mouse model of breast cancer. Cancer Research, 2023. e-Pub 2023.
- Bhardwaj A, Ju Z, Albarracin CT, Trinidad C, Mistretta B, Gunaratne P, Wang J, Zein RE, Bedrosian I. Subtype-specific molecular signatures of field cancerization in patients with sporadic breast cancer. Cancer Research, 2023. e-Pub 2023.
- Bhardwaj A, Rojo R, Ju Z, Koh A, Wang J, Bedrosian I. Molecular heterogeneity of multi-step breast tumorigenesis impacts the efficacy of cancer prevention drugs. Cancer Research, 2021. e-Pub 2021.
- Bhardwaj1 A, Embury1 MD, Rojo2 RD, 3, Albarracin4 C, Bedrosian1 I. Fluvastatin inhibits the development of breast cancer in SV40C3Tag mouse model of triple negative breast cancer. Cancer Research 80(16), 2020. e-Pub 2020.
- Bedrosian1 I, †, Ju2 Z, Bhardwaj1 A, Mistretta3 B, Gunaratne3 P, Wang2 J, Zein 4 RE. Identification of a subtype specific molecular field across the mammary gland of breast cancer patients. Cancer Research 80(16), 2020. e-Pub 2020.
- Bhardwaj A, Ju Z, Singh H, Embury M, Wang J, Bedrosian AI. A global increase in miRNAs and a concomitant decrease in tumor suppressor pathways define preneoplastic transition in TNBC. Cancer Research 79(13):773, 2019. e-Pub 2019.
- Bhardwaj, A, Singh, H, Rajapakshe, K, Coarfa, C, Bedrosian, I. Repurposing statins for prevention of triple negative breast cancer. Cancer Research 77(13):2220, 2017. e-Pub 2017.
- Bhardwaj, A, Tachibana, K, Rajapakshe, K, Ganeshan, N, Pan, Y, Gunaratne, P, Coarfa, C, Bedrosian, I. Targeting of miRNA networks for prevention of basal-like breast cancers. Cancer Research 75(15):3982, 2015. e-Pub 2015.
- Bhardwaj A, Rosen D, Liu M, Yan, Liu, Hao Q, Ganesan N, Etzel CJ, Gullett A, Albarracin CT, Bedrosian I. Suppression of Akt-mTOR pathway-a novel component of oncogene induced DNA damage response (DDR) barrier in breast. Cancer Research, 2013. e-Pub 2013.
- Meistrich ML, Zhao M, Weng CC, Bhardwaj A, Shetty AG. The Utp14b-jsd Mutation is responsible for a specific step in 18S Ribosomal RNA Processing in Mouse Spermatogenic Cells. Biology of Reproduction 81:76, 2009. e-Pub 2009.
- Bhardwaj A, Shanker S, Song, H, Wilkinson, MF. Spatial and temporal expression of Rhox5 homeobox gene in the epididymis is controlled by DNA methylation, androgen receptor, and GATA transcription factors. Biology of Reproduction:209, 2008. e-Pub 2008.
- MacLean JA, Hu ZY, Bhardwaj A, Wayne CM, Rao, MK, Wilkinson, MF. Rhox5 regulates key regulators of metabolism during testis development. Biology of Reproduction:84-85, 2006. e-Pub 2006.
- Wilkinson, MF, Bhardwaj A, Rao, M. AR and GATA factors collaborate to drive Sertoli cell specific expression of the Pem (Rhox-5) proximal promoter in the testis. Biology of Reproduction 118:163, 2005. e-Pub 2005.
- Bhardwaj A, Rao, M, Wilkinson, MF. Sertoli cell specific expression in the testis is directed by the regulatory sequences in Pem (Rhox-5) proximal promoter. Biology of Reproduction 726:259, 2004. e-Pub 2004.
Patient Reviews
CV information above last modified July 22, 2026